SCHEMBL1683239

SCHEMBL1683239

Cc1cc(C)c(N=Cc2ccccn2)c(C)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.61
MAOA P21397 2/20 0.59
MAOB P27338 1/20 0.53
GAA P10253 1/20 0.49
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 2/20 0.44
ATM Q13315 1/20 0.44
KDM4E B2RXH2 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5590327 1.00 NR4A1 (0.61) NR4A1MAOAMAOBGAAPTGS1
SCHEMBL5587889 0.98 NR4A1 (0.59) NR4A1MAOAMAOBGAAPTGS1
SCHEMBL3687480 0.90 NR4A1 (0.61) NR4A1MAOAMAOBGAAPTGS1
Hydrochloric Acid SCHEMBL3691304 0.87 NR4A1 (0.57) NR4A1MAOAMAOBGAAPTGS1
Hydrochloric Acid SCHEMBL3696298 0.87 NR4A1 (0.57) NR4A1MAOAMAOBGAAPTGS1
Hydrochloric Acid SCHEMBL3690303 0.87 NR4A1 (0.57) NR4A1MAOAMAOBGAAPTGS1
Bromide SCHEMBL3693147 0.87 NR4A1 (0.57) NR4A1MAOAMAOBGAAPTGS1
Bromide SCHEMBL3696741 0.87 NR4A1 (0.57) NR4A1MAOAMAOBGAAPTGS1
Bromide SCHEMBL3691157 0.87 NR4A1 (0.57) NR4A1MAOAMAOBGAAPTGS1
SCHEMBL5587206 0.86 NR4A1 (0.59) NR4A1MAOAMAOBGAAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025038960-A1 OLIGONUCLEOTIDES CONTAINING A LIGAND AT AN INTERNAL POSITION ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 WO disclosed
WO-2024249931-A1 PRMT5 INHIBITORS TARGETING MTAP DELETED CANCERS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-12-05 WO disclosed
WO-2024064769-A1 INDUCTION OF STEM-LIKE ACTIVATED T CELLS PHIO PHARMACEUTICALS CORP. (US) 2024-03-28 WO disclosed
WO-2023250342-A2 CYCLOPROPENE PHOSPHORAMIDITES AND CONJUGATES THEREOF Quantum-Si Incorporated (US) 2023-12-28 WO disclosed
WO-2023168077-A1 PHENOL-BASED HOT MELT ADHESIVES FOR REWORK, REPAIR AND RECYCLE CONAGEN INC. (US) 2023-09-07 WO disclosed
WO-2023154756-A2 THIONOLACTONES AS ADDITIVES FOR VINYL NETWORK DEGRADATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-08-17 WO disclosed
WO-2023139145-A1 SAPONIN-BASED ADJUVANTS AND VACCINES ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2023-07-27 WO disclosed
WO-2023099741-A1 SAPONIN-BASED ADJUVANTS AND VACCINES ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) 2023-06-08 WO disclosed
EP-4085136-A1 CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED SYSTEMIC DELIVERY Phio Pharmaceuticals Corp. (US) 2022-11-09 EP disclosed
EP-4055167-A2 CHEMICALLY MODIFIED OLIGONUCLEOTIDES TARGETING BROMODOMAIN CONTAINING PROTEIN 4 (BRD4) FOR IMMUNOTHERAPY Phio Pharmaceuticals Corp. (US) 2022-09-14 EP disclosed
EP-2598170-A2 DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO Smartcells, Inc. (US) 2013-06-05 EP disclosed
WO-2012015681-A2 DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO SMARTCELLS, INC. (US) 2012-02-02 WO disclosed
EP-2303897-A1 HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF President and Fellows of Harvard College (US) 2011-04-06 EP disclosed
WO-2009153769-A1 A BIOMATERIAL VYSERA BIOMEDICAL LIMITED (IE) 2009-12-23 WO disclosed
WO-2009149347-A1 HIGH-VALENT PALLADIUM FLUORIDE COMPLEXES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-12-10 WO disclosed
US-7247687-B2 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-07-24 US disclosed
EP-1521758-B1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEM PATENTS INC (US) 2006-05-24 EP disclosed
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. 2006-03-02 US disclosed
EP-1521758-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION Exxonmobil Chemical Patents Inc. (US) 2005-04-13 EP disclosed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization MLX, LOX, LMTK3 NR4A1 557/4885MAOA 242/4885MAOB 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.